Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000459240 | SCV000541189 | likely benign | Multiple endocrine neoplasia, type 1 | 2025-01-23 | criteria provided, single submitter | clinical testing | |
ARUP Laboratories, |
RCV001810944 | SCV001472733 | uncertain significance | not provided | 2020-07-24 | criteria provided, single submitter | clinical testing | The MEN1 c.1391C>T; p.Ala464Val variant (rs778728934), to our knowledge, is not reported in the medical literature. The variant is listed in the ClinVar database (Variation ID: 403807) and is reported in the South Asian population with an allele frequency of 0.05% (14/30252 alleles) in the Genome Aggregation Database. The alanine at codon 464 is moderately conserved, and computational analyses (SIFT, PolyPhen-2) predict that this variant is tolerated. Due to limited information, the clinical significance of the p.Ala464Val variant is uncertain at this time. |
Ambry Genetics | RCV002393072 | SCV002695998 | benign | Hereditary cancer-predisposing syndrome | 2023-08-08 | criteria provided, single submitter | clinical testing | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Myriad Genetics, |
RCV000459240 | SCV005403639 | likely benign | Multiple endocrine neoplasia, type 1 | 2024-08-08 | criteria provided, single submitter | clinical testing | This variant is considered likely benign. This variant has been observed at a population frequency that is significantly greater than expected given the associated disease prevalence and penetrance. |